These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12011303)

  • 1. Mifepristone (RU 486) for Alzheimer's disease.
    Pomara N; Doraiswamy PM; Tun H; Ferris S
    Neurology; 2002 May; 58(9):1436. PubMed ID: 12011303
    [No Abstract]   [Full Text] [Related]  

  • 2. The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease.
    Pomara N; Hernando RT; de la Pena CB; Sidtis JJ; Cooper TB; Ferris S
    Neurochem Res; 2006 May; 31(5):585-8. PubMed ID: 16770728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.
    Belanoff JK; Jurik J; Schatzberg LD; DeBattista C; Schatzberg AF
    J Mol Neurosci; 2002; 19(1-2):201-6. PubMed ID: 12212781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.
    Castinetti F; Brue T; Conte-Devolx B
    Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):295-9. PubMed ID: 22543346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone for management of Cushing's syndrome.
    Morgan FH; Laufgraben MJ
    Pharmacotherapy; 2013 Mar; 33(3):319-29. PubMed ID: 23436494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.
    Gallagher P; Watson S; Smith MS; Ferrier IN; Young AH
    Biol Psychiatry; 2005 Jan; 57(2):155-61. PubMed ID: 15652874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.
    Young AH; Gallagher P; Watson S; Del-Estal D; Owen BM; Ferrier IN
    Neuropsychopharmacology; 2004 Aug; 29(8):1538-45. PubMed ID: 15127079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease.
    DeBattista C; Belanoff J
    Curr Alzheimer Res; 2005 Apr; 2(2):125-9. PubMed ID: 15974908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.
    Fleseriu M; Molitch ME; Gross C; Schteingart DE; Vaughan TB; Biller BM
    Endocr Pract; 2013; 19(2):313-26. PubMed ID: 23337135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RU486 (mifepristone): mechanisms of action and clinical uses.
    Cadepond F; Ulmann A; Baulieu EE
    Annu Rev Med; 1997; 48():129-56. PubMed ID: 9046951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. It may take more than a shot: alternatives to immunotherapy for Alzheimer's disease.
    O'Banion MK
    Biol Psychiatry; 2013 Sep; 74(5):316-7. PubMed ID: 23932341
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical management of Cushing's syndrome.
    Vance ML
    Endocr Pract; 2013; 19(2):193. PubMed ID: 23598532
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mifepristone (Korlym) for Cushing's syndrome.
    Med Lett Drugs Ther; 2012 Jun; 54(1392):46-7. PubMed ID: 22683927
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiglucocorticoid therapy for older adults with anxiety and co-occurring cognitive dysfunction: results from a pilot study with mifepristone.
    Lenze EJ; Hershey T; Newcomer JW; Karp JF; Blumberger D; Anger J; Doré P; Dixon D
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):962-9. PubMed ID: 24633761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medical treatment of Cushing's syndrome: glucocorticoid receptor antagonists and mifepristone.
    Castinetti F; Conte-Devolx B; Brue T
    Neuroendocrinology; 2010; 92 Suppl 1():125-30. PubMed ID: 20829633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of mifepristone in the treatment of Cushing's syndrome.
    Carroll T; Findling JW
    Drugs Today (Barc); 2012 Aug; 48(8):509-18. PubMed ID: 22916338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large endometrial polyp in a patient on long-term mifepristone therapy.
    Martineau PA; Levental M
    J Ultrasound Med; 2000 Jul; 19(7):487-9. PubMed ID: 10898303
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial.
    Esteve JL; Acosta R; Pérez Y; Campos R; Hernández AV; Texidó CS
    Eur J Obstet Gynecol Reprod Biol; 2012 Apr; 161(2):202-8. PubMed ID: 22269473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mifepristone treatment of olanzapine-induced weight gain in healthy men.
    Gross C; Blasey CM; Roe RL; Allen K; Block TS; Belanoff JK
    Adv Ther; 2009 Oct; 26(10):959-69. PubMed ID: 19888560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.